Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling
Hye-Min Jeon, Yong Jae Shin, Jaehyun Lee, Nakho Chang, Dong-Hun Woo, Won Jun Lee, Dayna Nguyen, Wonyoung Kang, Hee Jin Cho, Heekyoung Yang, Jin-Ku Lee, Jason K. Sa, Yeri Lee, Dong Geon Kim, Benjamin W. Purow, Yeup Yoon, Do-Hyun Nam, Jeongwu Lee
Hye-Min Jeon, Yong Jae Shin, Jaehyun Lee, Nakho Chang, Dong-Hun Woo, Won Jun Lee, Dayna Nguyen, Wonyoung Kang, Hee Jin Cho, Heekyoung Yang, Jin-Ku Lee, Jason K. Sa, Yeri Lee, Dong Geon Kim, Benjamin W. Purow, Yeup Yoon, Do-Hyun Nam, Jeongwu Lee
View: Text | PDF
Research Article Development Oncology

The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling

  • Text
  • PDF
Abstract

Glioblastoma (GBM) is the most lethal brain cancer with a dismal prognosis. Stem-like GBM cells (GSCs) are a major driver of GBM propagation and recurrence; thus, understanding the molecular mechanisms that promote GSCs may lead to effective therapeutic approaches. Through in vitro clonogenic growth-based assays, we determined mitogenic activities of the ligand molecules that are implicated in neural development. We have identified that semaphorin 3A (Sema3A), originally known as an axon guidance molecule in the CNS, promotes clonogenic growth of GBM cells but not normal neural progenitor cells (NPCs). Mechanistically, Sema3A binds to its receptor neuropilin-1 (NRP1) and facilitates an interaction between NRP1 and TGF-β receptor 1 (TGF-βR1), which in turn leads to activation of canonical TGF-β signaling in both GSCs and NPCs. TGF-β signaling enhances self-renewal and survival of GBM tumors through induction of key stem cell factors, but it evokes cytostatic responses in NPCs. Blockage of the Sema3A/NRP1 axis via shRNA-mediated knockdown of Sema3A or NRP1 impeded clonogenic growth and TGF-β pathway activity in GSCs and inhibited tumor growth in vivo. Taken together, these findings suggest that the Sema3A/NRP1/TGF-βR1 signaling axis is a critical regulator of GSC propagation and a potential therapeutic target for GBM.

Authors

Hye-Min Jeon, Yong Jae Shin, Jaehyun Lee, Nakho Chang, Dong-Hun Woo, Won Jun Lee, Dayna Nguyen, Wonyoung Kang, Hee Jin Cho, Heekyoung Yang, Jin-Ku Lee, Jason K. Sa, Yeri Lee, Dong Geon Kim, Benjamin W. Purow, Yeup Yoon, Do-Hyun Nam, Jeongwu Lee

×

Figure 3

Sema3A activates TGF-β signaling via NRP1-TGF-βR1 interaction.

Options: View larger image (or click on image) Download as PowerPoint
Sema3A activates TGF-β signaling via NRP1-TGF-βR1 interaction.
(A) Co-IP...
(A) Co-IP IBs of NRP1 and TGF-βR1 in 131 GBM cells treated with rSema3A. For IP-IB data, Abs used for IP and Western blotting (WB) are labeled as red and blue, respectively. (B) Co-IP IBs of NRP1 and TGF-βRI in GBM cells treated with rSema3A or rVEGF165. (C) Left, representative images of PLAs using anti-NRP1 and anti–TGF-βR1 Abs. Red dots represent the positive signal due to the proximity of 2 added Abs. Alexa Fluor 488–conjugated phalloidin (green) and DAPI (blue) were used to visualize actin cytoskeleton and nuclei, respectively. Right, red dots were counted in 5 random fields and plotted. n = 5. Scale bar: 20 μm. (D and E) IBs of p-SMAD2 and total SMAD2 expression in GBM cells treated with or without rSema3A. n = 3. (F) IBs of p-SMAD2 in the NT control and NRP1-knockdown 559 GBM cells treated with or without rSema3A. (G) Immunostaining and quantitation of p-SMAD2 in the NT control and NRP1-knockdown 131 and 559 GBM cells treated with or without rSema3A. Scale bar: 50 μm. n = 4. (H) IBs of p-SMAD2, total SMAD2, p-KDR, and total KDR in 131 GBM cells treated with rSema3A (50 ng/mL) and rVEGF165 (100 ng/mL). Data represent mean ± SD. *P < 0.01 by 1-way ANOVA in C and E. *P < 0.01 by 1-way ANOVA with Tukey’s multiple-comparison test in G.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts